Abraxane in Treatment of Metastatic Breast Cancer

CompletedOBSERVATIONAL
Enrollment

203

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

February 28, 2016

Study Completion Date

December 31, 2016

Conditions
Metastatic Breast Cancer
Interventions
DRUG

nab-paclitaxel

nab-paclitaxel by IV infusion every 3 weeks until progression or toxicity

Trial Locations (13)

6800:

LKH Feldkirch, Feldkirch

8036:

Medical University Graz, Graz

6020:

Medical University Innsbruck, Innsbruck

8700:

LKH Leoben, Leoben

4020:

KH Barmherzige Schwestern Linz, Linz

5020:

LKH Salzburg, Salzburg

3100:

LKH St. Pölten, Sankt Pölten

4400:

LKH Steyr, Steyr

1090:

Medical University Vienna, Vienna

1220:

KH SMZ Ost, Vienna

4840:

LKH Vöcklabruck, Vöcklabruck

4600:

Klinikum Wels, Wels

2700:

LKH Wr. Neustadt, Wiener Neustadt

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Celgene

INDUSTRY